SCHEMBL864191

SCHEMBL864191

Clc1ccc2c(c1)OC1(CCNCC1)C2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.49
HTR2A P28223 2/20 0.43
HTR2B P41595 1/20 0.43
DRD2 P14416 2/20 0.38
PNMT P11086 1/20 0.38
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
OPRD1 P41143 1/20 0.35
F7 P08709 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11241821 0.98 HTR2C (0.48) HTR2CHTR2AHTR2BDRD2PNMT
SCHEMBL863813 0.94 HTR2C (0.50) HTR2CHTR2AHTR2BDRD2PNMT
SCHEMBL30172181 0.87 HTR2C (0.49) HTR2CHTR2AHTR2BDRD2PNMT
SCHEMBL1787224 0.87 HTR2C (0.49) HTR2CHTR2AHTR2BDRD2PNMT
Trifluoroacetic Acid SCHEMBL23093912 0.87 HTR2C (0.40) HTR2CHTR2AHTR2BDRD2MAPT
Hydrochloric Acid SCHEMBL10502464 0.86 HTR2C (0.48) HTR2CHTR2AHTR2BDRD2PNMT
SCHEMBL10192235 0.83 KDM4E (0.41) HTR2CDRD2MAP3K14
SCHEMBL10192220 0.83 KDM4E (0.41) HTR2CDRD2MAP3K14
SCHEMBL19030798 0.81 HTR2C (0.49) HTR2CHTR2ADRD2MAPTHDAC3
SCHEMBL25337824 0.81 HTR2C (0.49) HTR2CHTR2AHTR2BPNMTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021047677-A1 IRAK4 KINASE INHIBITOR AND PREPARATION THEREOF AND USE THEREOF 中国科学院上海药物研究所 2021-03-18 WO disclosed
EP-2440563-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2012-04-18 EP disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 US disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 US disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 US disclosed
WO-2010144571-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 HTR2C 133/4885HTR2A 83/4885HTR2B 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.